Disclosed are compounds to the treatment of infectious diseases and methods of treating such diseases. The compounds are derivatives of clevudine.

Disclosed herein are compounds having a structure according to Formula I and optionally Formula IV.

##STR00001##

The compounds may be radiolabeled compounds useful for diagnosis and/or imaging fungal infections. In such embodiments, at least one substituent is a radionuclide, such as .sup.18F. Also disclosed are precursor compounds according to Formula I and/or IV that are useful for making the radiolabeled compounds. In such embodiments, the precursor compound comprises at least one leaving group suitable for introducing a radionuclide, such as .sup.18F, at a desired position.

Also disclosed are methods for making and using the compounds, including embodiments of a method for imaging and/or diagnosing a fungal infection in a subject.

The present invention relates to a method for preparing a 2-fluoropurine marked with the radioisotope .sup.18F comprising a fluorination step for a 2-nitropurine derivative. The present invention comprises a 2-fluoropurine derivative marked with the radioisotope .sup.18F which can be obtained by or during a method according to the invention and its various uses.

Described herein are compounds that are useful for delivering therapeutic, diagnostic, and imaging agents. Also described herein are pharmaceutical compositions containing such compounds and methods of using the compounds and compositions. Also described are processes for manufacture of the compounds and the compositions containing them.

The present invention provides a system for evaporating a radioactive fluid, a method for the synthesis of a radiolabelled compound including this system, and a cassette for the synthesis of a radiolabelled compound comprising this system. The present invention provides advantages over known methods for evaporation of a radioactive fluid as it reduces drastically the amount of radioactive gaseous chemicals that are released in the hot cell. It is gentler and more secure compared to the known process and provides access to radiosyntheic processes that may not been acceptable for safety reasons related to release of volatile radioactive gases during evaporation. In addition, the process yields are higher because the radioactive volatiles are labelled intermediate species.

Described herein are methods and devices that allow the generation of [F-18]triflyl fluoride and other [F-18] sulfonyl fluorides (such as [F-18]tosyl fluoride) in a manner that is suitable for radiosynthesis of F-18 labeled radiopharmaceuticals using currently available synthesis modules.

Embodiments of the present disclosure provide for compounds and methods of making compounds such as those shown in FIG. 1.1A and 1.1B having formula 2, 3, 4, 5, 11, and 12 and formula 2′, 4′, and 11′, as well as uses for the compounds for imaging, and the like.

Disclosed are methods of forming an epimer or a dehydrated isomer of a pyranose monosaccharide or a pyranose saccharide residue in an oligosaccharide or a glycoside.

The present invention is directed towards new .sup.18F-folate radiopharmaceuticals, wherein the .sup.18F isotope is linked via a prosthetic group, more specifically via a prosthetic group having a saccharide group, such as a cyclic mono- or oligosaccharide, preferably based on a pyranoside or furanoside, which is covalently linked to the glutamate portion of a folate or derivative thereof, a method of their preparation, as well as their use in diagnosis and monitoring of cancer and inflammatory and autoimmune diseases and therapy thereof.

Provided is a new boron isotope (.sup.10B) tracing drug which can exhibit wide-area molecular-targeting function and stereotactic destructive power. The invented boron isotope (.sup.10B) tracing drug has higher selective tumor-targeting and tumor-accumulating pharmacokinetic functions appropriate for neutron beam dynamic therapy (NBDT) and boron neutron capture therapy (BNCT).